Answers are grounded in this paper and cite their sources.
HBV core protein (HBc) plays key roles in the viral lifecycle and hepatocarcinogenesis. While core protein allosteric modulators (CpAMs) have emerged as promising therapeutic agents, they are confronted with the issue of emerging drug resistance and lack the ability to degrade HBc. To surmount these challenges, by leveraging the class II CpAM NVR3-778 and an LC3 ligand ispinesib, we identified TK-96, a first-in-class autophagy-tethering compound (ATTEC) degrader, which induces the degradation of wild-type and drug-resistant HBc via the autophagic-lysosomal pathway. Remarkably, TK-96 exhibited subnanomolar antiviral potency in HepAD38 and HBV-infected HLCZ01 cells, indicating a more than 150-fold improvement in potency compared to NVR3-778. Furthermore, oral administration of TK-96 significantly inhibited viral replication and decreased hepatic HBc, as well as serum HBeAg and HBsAg levels, in an HBV carrier mouse model. Collectively, this study identifies a highly potent HBc degrader and underscores ATTEC-mediated degradation as a novel strategy for anti-HBV therapeutics.
No takes yet. Share an insight, caveat, or question.
Dou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: